Antineoplaston AS2-1 - oral

Drug Profile

Antineoplaston AS2-1 - oral

Alternative Names: Fengenal®

Latest Information Update: 04 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Burzynski Research Institute
  • Class Amino acids; Antineoplastons; Phenylacetates
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain cancer; Cancer metastases

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 18 Nov 2013 Five-year survival efficacy data from phase II trials in Brain cancer, including glioma released by Burzynski Clinic
  • 25 Jul 2013 No development reported - Phase-II for Brain cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top